INSERM UMR 1033, Université de Lyon, France.
Pathophysiology, Diagnosis & Treatments of Bone Diseases
Osteoporosis and bone metastasis induce structural alterations of the skeleton that lead to bone destruction and occurrence of pathological fractures. Despite of recent progress made to treat bone loss, there is clearly a need to better diagnose bone diseases and improve treatments of skeletal complications associated with bone diseases.
Our project aims at developing a translational research from basic scientific discoveries into clinical improvements in diagnosis and treatments of bone diseases.
Our scientific strategy hinges on 3 teams.
Team 1’s major objectives are to improve the prediction of fracture risk in men and women with osteoporosis. The relations between bone and certain chronic diseases will be also studied. It has become obvious (albeit little understood) that bone quality is influenced by chronic diseases and, conversely, that bone remodeling participates in the genesis of chronic diseases.
Team 2’s main objectives are to identify the underlying molecular mechanisms governing the nesting of tumour cells in the bone marrow and those that favour the formation of medullary micrometastases, the prelude required for bone metastasis formation. Additionally, new biological markers of early relapse of cancer in bone will be developed and novel therapeutics are being tested in animal models of malignant bone diseases.
Team 3’s main objectives are to study the roles of autotaxin and lysophosphatidic acid in bone physiology and benign (osteoporosis, rheumatoid arthritis) and cancerous (bone metastasis) bone pathologies.
Bone and chronic diseases
Bone, Cancers and Metastases
Lysophospholipids and Bone Pathophysiology
of the lab in figures:
- Staff: 57
- Basic and clinical scientists: 28
- Research Engineers and Technicians: 18
- Postdoctoral fellows and research students: 11
6 key most recent publications :
- REYNAUD C, FERRERAS L, DI MAURO P, KAN C, CROSET M, BONNELYE E, PEZ F, THOMAS C, AIMONT G, KARNOUB AE, BREVET M, CLEZARDIN P. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res. 2016 (in press).
- LEBLANC R, PEYRUCHAUD O. Metastasis: new functional implications of platelets and megakaryocytic. Blood. 2016 Jul 7;128(1):24-31.
- BOUTROY S, KHOSLA S, SORNAY-RENDU E, ZANCHETTA MB, McMAHON DJ, ZHANG CA, CHAPURLAT RD, ZANCHETTA J, STEIN EM, BOGADO C, MAJUMDAR S, BURGHARDT AJ, SHANE E. Microarchitecture and Peripheral BMD Are Impaired in Postmenopausal Caucasian Women with Fracture Independently of Total Hip T-Score – an International Multicenter Study. J Bone Miner Res. 2016 June;31(6): 1158-66.
- SAHAY D, LEBLANC R, GRUNEWALD TG, AMBATIPUDI S, RIBEIRO J, CLÉZARDIN P, PEYRUCHAUD O. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget. 2015 Aug 21;6(24):20604-20.
- LEBLANC R, LEE SC, DAVID M, BORDET JC, NORMAN DD, PATIL R, MILLER D, SAHAY D, RIBEIRO J, CLEZARDIN P, TIGYI GJ, PEYRUCHAUD O. Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. Blood. 2014 Nov 13;124(20):3141-50.
- CHRISTEN P, ITO K, ELLOUZ R, BOUTROY S, SORNAY-RENDU E, CHAPURLAT RD, van RIETBERGEN B. Bone remodelling in humans is load-driven but not lazy. Nat Commun. 2014 Sep 11;5:4855.